Abstract: Methods for preventing or treating brain neuronal diseases are provided. The methods include administering mesenchymal stem cells having increased agouti-related peptide (AgRP) expression or a conditioned medium thereof to a subject in need thereof. In some embodiments, the conditioned medium contains AgRP. The methods may further comprise administering ghrelin. The brain neuronal diseases include Alzheimer's disease, frontotemporal dementia, tauopathy, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, stroke, thrombosis, embolism, head trauma, cerebral circulatory or metabolic disorders, brain dysfunction, and dementia.

Abstract: The present invention relates to a composition for enhancing a survival rate of stem cells, including an immunosuppressant, and to a use thereof. According to the present invention, a survival rate of stem cells can be remarkably enhanced using a composition including an immunosuppressant, and a therapeutic effect of stem cells can be improved on the basis of the enhancement. The composition can overcome an immune response caused by the administration of xenogeneic cells so as to accurately verify the stability and efficacy of cells, and thus will be able to be utilized as a mesenchymal stem cell therapeutic agent that maximizes a therapeutic effect of stem cells.

Abstract: The present invention relates to a pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells.

Abstract: Disclosed is a producing method of a mesenchymal stem cell for brain neuronal disease prevention or treatment including ghrelin treatment, a composition for producing a mesenchymal stem cell for brain neuronal disease prevention or treatment, a mesenchymal stem cell produced by the producing method, and a pharmaceutical composition for prevention or treatment of brain neuronal disease containing the same. When using the producing method of the mesenchymal stem cells with the increased AgRP (Agouti related peptide) expression level according to the present disclosure, the mesenchymal stem cells produced by the method, or ghrelin, various brain neuronal diseases such as Alzheimer's disease may be effectively prevented or treated. When the composition for producing the mesenchymal stem cells with the increased AgRP expression level containing ghrelin according to the present disclosure is used, the mesenchymal stem cells with the increased AgRP expression level may be effectively produced.

Abstract: The present disclosure relates to a medium composition for enhancing proliferation of stem cells, comprising ethionamide, and a use thereof. It is possible, according to the present disclosure, to mass-produce highly-efficient next-generation stem cells through a simple and safe method of controlling a culturing environment, without using genetic modification or viral vectors, etc.

Abstract: The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.

Abstract: The present invention relates to a medium composition for improving stem cell migration, which includes ethionamide, and a use thereof. According to the present invention, the migration of stem cells may be effectively improved by the adjustment of a culture environment, which is a simple and safe method, without using gene manipulation or a viral vector, and the stem cells improved in migration by the method may be effectively used as a stem cell therapeutic agent that is able to function by rapidly migrating to the damaged region after transplantation.

Abstract: The present disclosure relates to a method for selecting mesenchymal stem cells having improved self-maintenance ability, wherein mesenchymal stem cells having excellent self-proliferative ability may be selected to reduce donor variation, and mesenchymal stem cells having excellent self-proliferative ability may be secured in large quantities and used for the development of cell therapy products.

Abstract: A method for culturing mesenchymal stem cells is disclosed. The method includes steps of: primary culturing mesenchymal stem cells in a medium containing umbilical cord blood serum; and subculturing the mesenchymal stem cells in a medium containing fetal bovine serum. The method for culturing mesenchymal stem cells may maintain stemness by reducing the differentiation and aging of stem cells, and in particular, may achieve a remarkably high proliferation rate.

Abstract: A cell death inhibitor including a mesenchymal stem cell genetically engineered to secrete growth-regulated oncogene-alpha (GRO-?) or overexpress GRO-? compared to a parent cell, GRO-?, or a combination thereof. A method of treating a muscle disease, including administering a pharmaceutically effective amount of a mesenchymal stem cell, which is genetically engineered to secrete growth-regulated oncogene-alpha (GRO-?) or overexpress GRO-? compared to a parent cell, or GRO-?, to a subject in need thereof.

Abstract: A method of culturing mesenchymal stem cells includes performing primary culture of umbilical cord-derived mesenchymal stem cells under hypoxic conditions with an oxygen partial pressure of 1 to 8% and pressure conditions of 1.0 to 8.0 PSI. The method of culturing umbilical cord-derived mesenchymal stem cells can maintain stemness by inhibiting the differentiation of stem cells and particularly can achieve a remarkably high proliferation rate.

Abstract: The present disclosure relates to a medium composition for enhancing proliferation of stem cells, comprising ethionamide, and a use thereof. It is possible, according to the present disclosure, to mass-produce highly-efficient next-generation stem cells through a simple and safe method of controlling a culturing environment, without using genetic modification or viral vectors, etc.

Abstract: Provided are a composition for ciliogenesis, containing a mesenchymal stem cell or a culture medium of mesenchymal stem cell. The mesenchymal stem cell or the culture medium of mesenchymal stem cell increases the number and promotes growth of primary cilia in cells. The mesenchymal stem cell or the culture medium of mesenchymal stem cell can be used as a pharmaceutical composition for preventing or treating diseases caused by ciliopathy or ciliary impairment. The mesenchymal stem cell or the culture medium of mesenchymal stem cell can be used as a cosmetic composition. A method for preventing or treating ciliopathy or ciliary impairment is disclosed.

Abstract: The present invention relates to a pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells.

Abstract: The present disclosure provides a pharmaceutical composition for treating Alzheimer's disease and use thereof, the pharmaceutical composition containing, as an active ingredient, stem cells (SC) having high adaptability under hypoxic conditions. Particularly, the present disclosure discloses a pharmaceutical composition for alleviating or treating the symptoms of Alzheimer's disease, the pharmaceutical composition containing, as an active ingredient, mesenchymal stem cells (MSC) which have high adaptability or viability in hypoxic environments and comprise one or more knock-out HIF1AN genes.

Abstract: The present invention relates to a human Lefty A protein variant with improved productivity and stability, a fusion protein comprising the protein variant, and a composition for preventing and/or treating neuromuscular disease comprising the protein variant or the fusion protein. According to the present invention, a human Lefty A protein variant and a fusion protein comprising the variant are constructed, which have better stability than naturally occurring human Lefty A protein, and thus are expressed at high levels and produced in high yield in animal cells. In addition, administration of the constructed human Lefty A protein variant or fusion protein can restore the nerve and motor functions of nerve disease model animals. Accordingly, the use of the human Lefty A protein variant or fusion protein can effectively prevent or treat various nerve diseases and muscle diseases.

Abstract: The present invention relates to a composition for enhancing a survival rate of stem cells, including an immunosuppressant, and to a use thereof. According to the present invention, a survival rate of stem cells can be remarkably enhanced using a composition including an immunosuppressant, and a therapeutic effect of stem cells can be improved on the basis of the enhancement. The composition can overcome an immune response caused by the administration of xenogeneic cells so as to accurately verify the stability and efficacy of cells, and thus will be able to be utilized as a mesenchymal stem cell therapeutic agent that maximizes a therapeutic effect of stem cells.

Abstract: Disclosed is a producing method of a mesenchymal stem cell for brain neuronal disease prevention or treatment including ghrelin treatment, a composition for producing a mesenchymal stem cell for brain neuronal disease prevention or treatment, a mesenchymal stem cell produced by the producing method, and a pharmaceutical composition for prevention or treatment of brain neuronal disease containing the same. When using the producing method of the mesenchymal stem cells with the increased AgRP (Agouti related peptide) expression level according to the present disclosure, the mesenchymal stem cells produced by the method, or ghrelin, various brain neuronal diseases such as Alzheimer's disease may be effectively prevented or treated. When the composition for producing the mesenchymal stem cells with the increased AgRP expression level containing ghrelin according to the present disclosure is used, the mesenchymal stem cells with the increased AgRP expression level may be effectively produced.

Abstract: The present application relates to a marker gene for detecting the proliferative ability of stem cells and uses thereof, and provides a marker detection composition for detecting the proliferative ability of stem cells, a kit for detecting the proliferative ability of stem cells, and a composition for improving the proliferative ability of stem cells, etc. According to the composition or method according to an aspect, stem cells having a high proliferative ability may be easily selected, and the proliferative ability of stern cells may be significantly improved.

Abstract: The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.